Roanoke earns Bee Campus USA certification
The certification process was led by a team of environmental studies majors.
SALEM, Va., May 10, 2025 /PRNewswire/ -- Roanoke College is proud to announce that it's been certified as a Bee Campus USA site, recognizing its commitment to pollinator-friendly practices that support vital environmental needs.
Roanoke is the 200th college or university nationwide to join the Bee Campus USA movement. Its certification process was spearheaded by students majoring in environmental studies who were inspired to turn what they were learning into tangible action right here on campus.
'We wanted to show how even small changes can be part of a big impact,' said James Hartmann '25, one of five students who proposed the project as part of their senor practicum, a course that challenged them to tackle a real-world issue.
Bee Campus USA is a national program designed to marshal the strengths of higher ed campuses to create better habitats for bees and other pollinators essential to our ecosystem. Collectively, pollinators support the growth of over 85% of flowering plants and 65% of agricultural crops. This year, a new study concluded that one in five pollinators in North America is at an elevated risk of extinction.
As part of its Bee Campus USA certification, Roanoke reaffirmed its commitment to pro-pollinator landscape management practices, including the use of native plants on campus. Hartmann and classmates also added a pollinator plant section to the campus garden, where the Roanoke College Beekeeping Society maintains a hive and plans to add a second one next month.
Pollinator habitats also are supported on Elizabeth Campus, where the Roanoke College Environment Center is restoring about five acres of meadows, woods, and creek swales. In 2024, it was able to install bat houses and bee houses, thanks to grants from the National Wildlife Federation, Mutual of Omaha's Wild Kingdom College and University Grant Program, and the Virginia Environmental Endowment Community Conservation Program.
'Bee Campus USA certification is a wonderful acknowledgment of the work our campus is doing to create a healthier environment for pollinators,' said Professor Kathy O'Neill, chair of environmental studies at Roanoke. 'Pollinators play a crucial role in our ecosystems, and we're proud to be part of a national effort to protect them.'
More information is available at beecityusa.org.
View original content: https://www.prnewswire.com/news-releases/roanoke-earns-bee-campus-usa-certification-302451542.html
SOURCE Roanoke College
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
24 minutes ago
- Gizmodo
Trump's Cuts Threaten Nobel-Winning Observatory That Detected Colliding Black Holes
Nearly 10 years ago, scientists observed ripples in spacetime created by the collision of two black holes that took place 1.3 billion years ago. The first direct detection of gravitational waves opened up an entirely new way of seeing the universe, allowing us to observe a once invisible side of the cosmos. Today, the ability to track the frequencies produced by the most notable events that shape our surrounding cosmos is at risk due to drastic budget cuts targeting a breakthrough observatory. In late May, the U.S. administration released a so-called skinny budget that highlighted the proposed funds allocated to NASA and the National Science Foundation in 2026. As part of several monstrosities committed against ongoing science programs, the proposed budget would gut the funding for the Laser Interferometer Gravitational-Wave Observatory (LIGO) by 39.6%. The budget request allocates $29 million instead of $48 million for LIGO, and shuts down one of its two interferometers. The twin interferometers are situated 1,865 miles apart (3,002 kilometers), with one facility in Washington State and another in Louisiana. The enormous research facilities operate in unison as a single observatory designed to detect gravitational waves, ripples in spacetime that travel at the speed of light. Unlike other telescopes, LIGO is blind. It detects gravitational waves by measuring incredibly small distortions in spacetime. Using its laser interferometers, it splits a laser beam into two and sends each of them down two long vacuum-sealed arms. The beams travel back and forth through each arm, bouncing between precisely configured mirrors. Each beam monitors the distance between the mirrors and detects tiny changes caused by gravitational waves, which can stretch space in one direction and compress it in the other. The lasers can discern movements between their mirrors with an accuracy of 1/10,000th the width of a proton. Researchers from Caltech and MIT, with funding and oversight from the National Science Foundation, completed construction of LIGO—one of the world's most sophisticated scientific observatories—in 1999. Scientists spent years searching for gravitational waves and coming up empty. Finally, on September 14, 2015, the observatory began picking up the signal of its first gravitational waves. The groundbreaking detection provided scientists with a brand new way of observing the universe, allowing them to trace the waves back to events that had long remained hidden in the cosmos. Gravitational waves are caused by the merger of black holes, the collision of neutron stars, and asymmetric supernovae. Some may have also been produced in the early universe, moments after the Big Bang. Three researchers behind LIGO's discovery were awarded the Nobel Prize in Physics in 2017 for their role in the detection of gravitational waves: physicists Rainer Weiss, Barry Barish, and Kip Thorne. These ripples in spacetime were first predicted by Albert Einstein in 1916, and could only be confirmed decades later. The first discovery was confirmed because the signal was observed by both LIGO detectors. Since then, the twin LIGO interferometers—sometimes in coordination with the Virgo observatory in Italy—have detected hundreds of additional gravitational wave signals. Gravitational waves produce a high-pitched chirp when translated to audio, beginning at a low frequency. The two interferometers, and sometimes three, need to work in unison to confirm these faint signals. If one of LIGO's twin interferometers is shut down, as is suggested by the proposed budget, researchers would have trouble distinguishing between a black hole collision and a nearby seismic tremor, according to Science. The field of gravitational waves is only just getting started thanks to the twin LIGO detectors. Killing off one of the laser interferometers would hinder our newfound ability to listen in to the soft ripples of spacetime that echo through the cosmos.
Medscape
36 minutes ago
- Medscape
Lymphoma: Dual-Targeting CAR T Shows Safety, Efficacy
In a first in-human study, KITE-363, an anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy, showed high rates of response in patients with highly refractory large B-cell lymphoma (LBCL). The bicistronic, autologous CAR T-cell therapy, designed to prevent CD19 escape through the upfront targeting of CD19 and CD20, also showed an encouraging safety profile, with no dose-limiting toxicities. METHODOLOGY: The phase 1, open-label, multicenter study enrolled adult patients with LBCL, indolent non-Hodgkin lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, or mediastinal gray zone lymphoma. Following lymphodepleting chemotherapy, patients were treated with KITE-363 at dose levels of 1, 2, or 3, corresponding to 0.5 × 10 6 , 1 × 10 6 , and 2 × 10 6 CAR T cells per kilogram, respectively. , 1 × 10 , and 2 × 10 CAR T cells per kilogram, respectively. Among 37 patients who were eligible and treated, the majority (73%) had advanced stage III or IV disease, and all were highly refractory, with more than two prior lines of therapy. The median age of patients was 62 years, with more than 10% of those in the study older than 75 years. TAKEAWAY: At a median follow-up of 11.2 months, the outcomes for CAR T-naive patients treated at dose level 3 (n = 23; 2 × 10 6 CAR T cells per kilogram), which is the recommended dose for phase 2 trials, showed an overall response rate (ORR) of 87%, while the complete response (CR) rate was 78%. CAR T cells per kilogram), which is the recommended dose for phase 2 trials, showed an overall response rate (ORR) of 87%, while the complete response (CR) rate was 78%. All seven patients (100%) with LBCL who were CAR T-naive after two or more lines of therapy and who received dose level 3 had a CR. Of the 15 patients receiving dose level 3 who were primary refractory, the ORR was 80% and the CR rate was 67%. The median duration of CR was not reached, while the 6-month duration of CR was 71.4%. Overall, no dose-limiting toxicities occurred. There were no grade 3 or higher reports of cytokine release syndrome (CRS). Two cases of grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred with short durations; however, no cases occurred among those receiving dose level 3, with primary refractory LBCL (n = 15). IN PRACTICE: 'KITE-363 demonstrated high responses in patients with highly refractory LBCL, including those with primary refractory disease,' said first author Saurabh Dahiya, MD, of the Stanford University School of Medicine, in Stanford, California. 'We observed no grade 3 or 4 CRS or ICANS in this study, which is a sharp contrast to the current FDA-approved CAR T-cell therapies,' he said. 'Taken together, these results support KITE-363 as a promising therapeutic approach for patients with R/R [relapsed or refractory] B-cell lymphoma, including those with highly refractory LBCL,' Dahiya added. 'Given the promising early results and specifically robust CAR T expansion and good safety profile, KITE-363 is now being developed for the treatment of autoimmune conditions.' SOURCE: This study was presented in Chicago at American Society of Clinical Oncology (ASCO) 2025. DISCLOSURES: This study was funded by Kite, a Gilead Company.
Medscape
an hour ago
- Medscape
DIF Microscopy Helps Diagnose Pediatric Skin Diseases
Direct immunofluorescence (DIF) microscopy showed a 15.5% positivity rate in pediatric patients and changed the clinical diagnosis in 16.7% of those cases. METHODOLOGY: Researchers conducted a retrospective review of DIF data from 986 patients aged 0-18 years (mean age, 12 years) at the Mayo Clinic's reference immunodermatology laboratory between August 2017 and November 2023. Biopsy sites included head and neck (cutaneous), head and neck (mucosal), trunk, pelvic region, upper extremities, and lower extremities. Results were classified as positive if characteristic immunofluorescence patterns were observed (pemphigoid pattern, pemphigus pattern, lupus pattern, dermatitis herpetiformis pattern, linear immunoglobulin A [IgA] bullous dermatosis pattern, vasculitis/vasculopathy pattern, or lichenoid tissue reaction pattern). During the same period, 40,859 DIF specimens from adults were also interpreted. TAKEAWAY: The DIF positivity rate was 15.5% in children and 20.9% in adult specimens. IgA-predominant vasculitis was the most frequent DIF pattern in children (55.5%), followed by lichenoid tissue reaction (13.7%), pemphigoid disorders (7.2%), lupus (7.2%), dermatitis herpetiformis (5.2%), linear IgA bullous dermatosis (4.6%), pemphigus (3.3%), and non-IgA predominant vasculitis (3.3%). Of the 114 positive DIF patterns with a pretest diagnosis, researchers observed 'relatively high' concordance between the clinical pretest diagnosis and DIF results (83.3%), but in 16.7% of cases, the initial clinical impression differed from positive DIF results. Linear IgA bullous dermatosis (100%) and dermatitis herpetiformis (100%) showed the highest concordance. Specimens from the lower extremities showed the highest yield of positive DIF compared with all other sites (19.7% vs 12.2%; P = .001). IN PRACTICE: The study findings showed that 'similar thresholds for DIF biopsy are held' for pediatric and adult patients and 'high concordance rates between positive DIF studies and clinical pretest diagnosis imply acceptable test specificity,' the study authors wrote. 'The study demonstrated that DIF results provided information that changed the clinical impressions in a substantial percentage of cases, supporting the utility of DIF biopsy when immune-mediated dermatoses are clinically suspected,' they added. SOURCE: The study was led by Clint Christian T. Garbanzos, MD, Department of Pathology and Laboratory Medicine, MedStar Georgetown University Hospital, Washington, DC, and was published online on May 29 in Pediatric Dermatology . LIMITATIONS: Limitations included the retrospective design and lack of a negative analysis. False-positive and false-negative results could not be determined. DISCLOSURES: This study was supported by the American Society of Dermatopathology Mentorship in Dermatopathology Award. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. Credit Lead image: Frontline Medical Communications Medscape Medical News © 2025 WebMD, LLC Cite this: Edited by Deepa Varma. Direct Immunofluorescence Microscopy Helps Diagnose Pediatric Skin Diseases - Medscape - June 13, 2025.
